Weight loss drug Wegovy is now approved for heart health — but that won’t mean broad insurance coverage just yet
Some health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say
Read MoreSome health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say
Read MoreThe FDA's decision means Madrigal has succeeded in a disease area that several larger companies have failed — or are
Read MoreWhile weight loss drugmakers are catching a bid with investors, experts are less certain that ETFs linked to the category
Read MoreAmazon Pharmacy second online pharmacy to partner with Eli Lilly's site, and could provide faster deliveries for certain patients. Source
Read MoreThat decision could widen insurance coverage for the drug and similar treatments for obesity, which has been a major barrier
Read MoreLars Fruergaard Jørgensen's remarks came one day after Novo Nordisk impressed investors with early-stage trial data on amycretin. Source link
Read MoreWegovy obesity drug maker Novo Nordisk surpassed Tesla in market value Thursday after fresh early trial data showed positive results
Read MoreNovo Nordisk shares climbed 5% on Thursday morning after the Danish pharmaceutical giant reported positive early trial data for a
Read MoreSome Wall Street analysts said Viking's experimental obesity treatment may be "best-in-class" following the release of midstage trial data. Source
Read More